Adamas Pharmaceuticals, Inc.

True Health IP LLC

Investigen, Inc.

Health Diagnostics Laboratory, Inc.

Mickey S Urdea

Timothy J Fultz

Gregory T Went

Terry L Burkoth

Patrick A Arensdorf

Michael P McKenna

David Chernoff

Jack Nguyen

Paul Spence

Rowan Chapman

Brian David Warner

Heather Koshinsky

Michael Steven Zwick

Rachel Anne Holmes-Davis

Charles Robert Bupp, Ii

K Yeon Choi

Miaomiao Wang

Alexander Izmailov

Christopher Jon Nulf

Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluating the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease.

Markers associated with arteriovascular events and methods of use thereof

Methods of determining the presence or amount of a target polynucleotide in a sample are provided. A sample that contains a target polynucleotide, a polynucleotide that may include nucleic acid analogs and that is complementary to a target nucleic acid sequence of the target polynucleotide, and a dye for which the rate of change in an optical property is different in the presence and absence of a target polynucleotide/polynucleotide hybrid are combined to produce a reaction mixture. The rate of change in an optical property of the dye in the reaction mixture is compared to a reference value characteristic of the rate of change in the optical property of the dye in a similar reaction mixture containing a known amount of a polynucleotide/polynucleotide hybrid to determine a relative rate of change in the optical property. The relative rate of change in the optical property of dye in the reaction mixture is correlated with the presence or amount of the specified target polynucleotide in the sample.

Methods and compositions for detecting polynucleotides

Kits comprising an M2 inhibitor selected from amantadine and rimantadine; ribavirin, and a neuraminidase inhibitor (NAi) in an amount that is antivirally effective in the combination, an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin and a neuraminidase inhibitor are provided for the treatment of influenza. Some embodiments of the kits comprise an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin, and a neuraminidase inhibitor.

Compositions and kits for treating influenza

Compositions, kits and methods are provided for the treatment or prophylaxis of influenza.

Growing community of inventors

Alamo, CA, United States of America

Mickey S Urdea